Duchenne Muscular Dystrophy News and Research

RSS
Duchenne muscular dystrophy (DMD) is a progressive muscle disorder that causes the loss of both muscle function and independence. DMD is perhaps the most prevalent of the muscular dystrophies and is the most common lethal genetic disorder diagnosed during childhood today. Each year, approximately 20,000 children worldwide are born with DMD (one of every 3,500 male children).
Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

Tβ4 may help treat skeletal muscle disease in Duchenne muscular dystrophy

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

BioMarin announces update on BMN 110 Phase I/II trial for Morquio A Syndrome

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

BioMarin Pharmaceutical signs stock purchase agreement to acquire LEAD Therapeutics

A novel approach for funding children's genetic disease research

A novel approach for funding children's genetic disease research

Link between dystrophin gene and age of cardiac disease onset in BMD patients identified

Link between dystrophin gene and age of cardiac disease onset in BMD patients identified

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

BioMarin Pharmaceutical commences BMN 195 Phase 1 clinical study for DMD

AMT receives Innovation Credit to develop gene therapy treatment for DMD

AMT receives Innovation Credit to develop gene therapy treatment for DMD

Kennedy Krieger Institute opens new center for individuals with muscle disorders

Kennedy Krieger Institute opens new center for individuals with muscle disorders

Humans and mice have critical differences in gene responsible for DMD

Humans and mice have critical differences in gene responsible for DMD

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Amsterdam Molecular Therapeutics provides third-quarter 2009 business updates

Galapagos third quarter 2009 financial results in line with management expectations

Galapagos third quarter 2009 financial results in line with management expectations

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Gene therapy increases muscle size and strength with no adverse effects in monkeys: MDA

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

Gene delivery strategy to help improve muscle mass in patients with degenerative muscle disorders

AMT's gene therapy successful in treating Duchenne muscular dystrophy

AMT's gene therapy successful in treating Duchenne muscular dystrophy

PPMD awards $75,000 grant to University of California professor for Duchenne muscular dystrophy research

PPMD awards $75,000 grant to University of California professor for Duchenne muscular dystrophy research

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

Research shows exon-skipping drug may prove effective for treating Duchenne muscular dystrophy

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

Amsterdam Molecular Therapeutics' AMT-080 granted EMEA Orphan Drug Designation

Macrophages play a crucial role in muscle regeneration

Macrophages play a crucial role in muscle regeneration

Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug

Charley's Fund and the Nash Avery Foundation to support investigation of Galapagos' SARM candidate drug

Safeway raises funds to support neuromuscular disease medical research and therapies

Safeway raises funds to support neuromuscular disease medical research and therapies